REWIND
Retrospective Real-World Interpretation of Data
Objective
This study will validate real-world applicability of EMBRACE II findings, particularly concerning dose-volume constraints and the feasibility of concurrent chemotherapy.
This multicenter, non-interventional retrospective observational cohort study will include LACC patients treated with MR-IGABT at EMBRACE II centers in 2021 and 2022. Data will be collected on patient demographics, tumor characteristics, treatment details, and clinical outcomes. EviGUIDE will be used to analyze dosimetric parameters and predict clinical outcomes. Descriptive statistics and Kaplan-Meier survival analysis, will be conducted to compare outcomes with EMBRACE II benchmark.
Principal Investigator
